MAM
CPRX

Marquette Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Marquette Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Hold
83
– – ﹤0.01% 544
2026
Q1 		$2.06K Hold
83
– – ﹤0.01% 533
2025
Q4 		$1.94K Hold
83
– – ﹤0.01% 486
2025
Q3 		$1.64K Buy
+83
New +$1.71K ﹤0.01% 602

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Marquette Asset Management's CPRX Position: Q2 2026 in Review

Marquette Asset Management held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 83 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #544.

Marquette Asset Management first reported a position in CPRX in Q3 2025 and has held it in 4 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Marquette Asset Management held 83 shares of Catalyst Pharmaceutical worth $2.61K as of Q2 2026.
  • Marquette Asset Management left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #544 holding.
  • Marquette Asset Management first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 4 quarters since.
  • 36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.